Abstracts tagged "Patient reported outcomes"

Abstract Number: 2624 • ACR Convergence 2025
Results of Large Multi-Site Pragmatic Clinical Trial Comparing Corticosteroids or Blinded Lidocaine-only Injections in Treating Osteoarthritis of the Knee
Joshua Baker¹, Katherine Wysham², Mercedes Quinones³, Bryant England⁴, Kaitian Jin¹, Marianna Olave⁵, Sarah Wetzel⁶, Rachel Gillcrist⁷, Criswell Lavery¹, Natalie Keller⁸, Kimberly Hayes⁹, Bridget Kramer⁴, Hannah Brubeck¹⁰, Bibiana Ateh¹¹, Daniel K. White¹², Alexis Ogdie¹³, Rui Xiao¹, Tuhina Neogi¹⁴ and Carla Scanzello¹, ¹University of Pennsylvania, Philadelphia, PA, ²VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ³Washington DC VA Medical Center, Bethesda, MD, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Brown University, Philadelphia, PA, ⁶Drexel University, Pittsburgh, PA, ⁷Dartmouth College, Lebanon, NH, ⁸University of Oklahoma, Philadelphia, PA, ⁹Teachers College, Columbia University, Philadelphia, PA, ¹⁰VA Puget Sound Health Care System, Seattle, WA, ¹¹Washington VA Medical Center, Washington, District of Columbia, ¹²University of Delaware, Newark, DE, ¹³Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ¹⁴Boston University School of Medicine, Boston, MA
Background/Purpose: Intra-articular corticosteroids are widely used for routine management of chronic pain from knee osteoarthritis (KOA), though estimates of their benefit vary widely. We aimed…
Abstract Number: 2263 • ACR Convergence 2025
Comparison of a Patient-Reported Disease Activity Measure with Physician-Based Indices in Rheumatoid Arthritis Patients in Nigeria
Uchechukwu Tralagba¹, Courage Uhunmwangho², Olufemi Adelowo³, Henry Nwankwo⁴, Dasetima Altraide¹, Ejiehi Aigbokhan⁵, Ako Itam⁶, Omokhowa Asekhame⁴ and Hakeem Olaosebikan³, ¹University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers, Nigeria, ²Jos University Teaching Hospital, Jos, Plateau, Nigeria, ³Lagos state university teaching hospital, Ikeja, Lagos, Nigeria, ⁴Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra, Nigeria, ⁵University of Benin Teaching Hospital, Benin, Edo, Nigeria, ⁶University of Calabar Teaching Hospital, Calabar, Cross River, Nigeria
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by chronic inflammation of synovial joints with extra articular manifestations. Disease activity indices in Rheumatoid…
Abstract Number: 1569 • ACR Convergence 2025
Can We Use Patient Reported Outcomes For Home-monitoring in SSc?
Eva Hoekstra¹, Katherine van der Wouden², Queeny Madari¹, Saad Ahmed³, Lianne Kwant¹, Ada Hortensius-Varkevisser¹, Emiel Marges¹, Jacopo Ciaffi⁴, Anne Schouffoer⁵, Tom Huizinga⁶ and Jeska de Vries-Bouwstra⁶, ¹Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Center and Amsterdam University Medical Center, Leiden, Zuid-Holland, Netherlands, ³LUMC, Leiden, Netherlands, ⁴IRCCS Istituto Ortopedico Rizzoli, Bologna, Bologna, Italy, ⁵HagaZiekenhuis the Hague, the Hague, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Home-monitoring is a suitable strategy to reduce the frequency of hospital visits, and alleviate strain on healthcare resources. However, in systemic sclerosis (SSc) this…
Abstract Number: 1278 • ACR Convergence 2025
Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus
Emily Masi¹, Kimberly Rapoza², Tamar Rubinstein³, Kathy Kenney-Riley⁴ and Joyce Hui-Yuen⁵, ¹Cohen Children's Medical Center, North New Hyde Park, NY, ²Mercy College, Dobbs Ferry, NY, ³Albert Einstein College of Medicine, White Plains, NY, ⁴Mercy University, Dobbs Ferry, NY, ⁵North Shore LIJ Health System, Great Neck, NY
Background/Purpose: Patient and provider discordance can negatively impact medication adherence and disease outcomes in pediatric lupus. Functional status is known to greatly affect perception of…
Abstract Number: 0640 • ACR Convergence 2025
Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study
Vibeke Strand¹, Zahi Touma², Anca Askanase³, Christopher Saffore⁴, Denise Kruzikas⁵, Karim Masri⁵, Siran Fang⁵, Yi Peng⁶, Patti Katz⁷ and Marta Mosca⁸, ¹Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ²University of Toronto, Toronto, ON, Canada, ³Columbia University Medical Center, New York, NY, ⁴AbbVie Inc., waukegan, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., Maple Grove, MN, ⁷UCSF, San Rafael, CA, ⁸University of Pisa, Pisa, Pisa, Italy
Background/Purpose: This analysis evaluated associations between clinically important improvements in patient-reported outcomes (PROs) and reduced disease activity from the phase 2 SLEek trial evaluating upadacitinib…
Abstract Number: 0386 • ACR Convergence 2025
Introducing the Multidimensional Pain Inventory as a Comprehensive Tool or Assessing Pain in Patients With Axial Spondyloarthritis
David Kiefer¹, Yade Sonkaya², Dietmar Krause³, Markus Voglau⁴, Bernhard Mintrop⁵, Imke Redeker⁶, Xenofon Baraliakos⁷ and Uta Kiltz⁷, ¹Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, ²Ruhr-Universität Bochum, Herne, Germany, ³Elisabeth-Gruppe, Herne, Germany, Essen, Germany, ⁴myself, Oldenburg, Germany, ⁵Private rheumatology practice, Hattingen, Germany, ⁶Ruhr University Bochum, Bochum, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: The West Haven-Yale Multidimensional Pain Inventory (MPI) is a validated tool designed to assess the multidimensional aspects of chronic pain, including the 5 dimensions…
Abstract Number: 0225 • ACR Convergence 2025
Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses
Juan Schmukler¹, Tengfei Li² and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: Comorbid anxiety (ANX), depression (DEP), and fibromyalgia(FM) are reported as more common in patients with rheumatoid arthritis (RA) and other rheumatic diagnoses than in…
Abstract Number: 2578 • ACR Convergence 2025
Association of Oral Outpatient Antiviral Medications for COVID-19 with the Risk of Post-Acute Sequelae of COVID-19 in Individuals with Systemic Autoimmune Rheumatic Diseases
Madison Negron¹, Jiaqi Wang², Xiaosong Wang³, Lauren O'Keeffe⁴, Grace Qian⁴, Kevin Mueller⁴, Alene Saavedra⁴, Natalie Davis⁵, Liya Sisay Getachew⁶, Jeffrey Sparks⁶ and Naomi Patel⁷, ¹Harvard Extension School, Medford, MA, ²Massachusetts General Hospital, BOston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Massachusetts General Hospital, Boston, MA
Background/Purpose: Prior studies have evaluated the efficacy of antiviral medications on acute outcomes of COVID-19 infection as well as the risk of post-acute sequelae of…
Abstract Number: 2234 • ACR Convergence 2025
Early Sustained Remission Resulted in Superior Long-term Patient-Reported Outcomes in Rheumatoid Arthritis
Cheuk Yin Tam, Ho So and Lai Shan Tam, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: This study compared the impact of achieving early sustained remission (sREM) versus early sustained low disease activity (sLDA) on patient-reported outcomes (PROs) after 5…
Abstract Number: 1566 • ACR Convergence 2025
Factors Associated with Patient and Physician Global Assessments in Early Systemic Sclerosis
Ellen Romich¹, Alexis Ogdie², Peter Merkel³, Alisa Stephens Shields³, Jessica Alvey⁴, Shervin Assassi⁵, Elana Bernstein⁶, Sonali Bracken⁷, Flavia Castelino⁸, Lorinda Chung⁹, Luke Evnin¹⁰, Tracy Frech¹¹, Jessica Gordon¹², Faye Hant¹³, Monica Harding¹⁴, Laura Hummers¹⁵, Dinesh Khanna¹⁶, Kimberly Lakin¹², Dorota Lebiedz-Odrobina¹⁴, Yiming Luo⁶, Ashima Makol¹⁷, Maureen Mayes¹⁸, Zsuzsanna McMahan¹⁹, Jerry Molitor²⁰, Duncan Moore²¹, Carrie Richardson²², Ami Shah¹⁵, Ankoor Shah²³, Brian Skaug²⁴, Virginia Steen²⁵, John VanBuren¹⁴, Elizabeth Volkmann²⁶, Carleigh Zahn¹⁶ and Nora Sandorfi³, ¹University of Pennsylvania, Media, PA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ³University of Pennsylvania, Philadelphia, PA, ⁴Utah Data Coordinating Center, University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁶Columbia University, New York, NY, ⁷Duke University Medical Center, Durham, NC, USA, Apex, NC, ⁸Massachusetts General Hospital, Boston, MA, ⁹Stanford University, Stanford, CA, ¹⁰Scleroderma Research Foundation, San Francisco, CA, ¹¹Vanderbilt University Medical Center, Nashville, TN, ¹²Hospital for Special Surgery, New York, NY, ¹³Medical University of South Carolina, Charleston, SC, ¹⁴University of Utah, Salt Lake City, UT, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶University of Michigan, Ann Arbor, MI, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸UT Health Houston Division of Rheumatology, Houston, TX, ¹⁹UT Health Houston, Houston, TX, ²⁰University of Minnesota, Minneapolis, MN, ²¹Northwestern Memorial Hospital, Chicago, IL, ²²Northwestern University, Chicago, IL, ²³Duke University, Durham, NC, ²⁴UTHealth Houston Division of Rheumatology, Houston, TX, ²⁵Georgetown University School of Medicine, Washington, DC, ²⁶Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Global assessments by patients and physicians provide unique but complementary perspectives of disease severity. This study aimed to determine the clinical and patient-reported factors…
Abstract Number: 1267 • ACR Convergence 2025
Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
Leah Santacroce¹, Misti Paudel² and Daniel Solomon³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ³Brigham and Women's Hospital, Newton, MA
Background/Purpose: Patient Reported Outcomes (PROs) collected via a mobile health application (App) can provide valuable insight into the health of patients with Rheumatoid Arthritis (RA).…
Abstract Number: 0573 • ACR Convergence 2025
Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Joseph F Merola¹, Alexis Ogdie², Alice B. Gottlieb³, Fabian Proft⁴, Nuala Brennan⁵, Alex Godwood⁵, Matthew R. Thomas⁵, Eva Cullen⁵, Kristian Reich⁶, Laura Coates⁷ and Laure Gossec⁸, ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, ⁴Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵MoonLake Immunotherapeutics AG, Zug, Switzerland, ⁶MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁸Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Sonelokimab (SLK) is a novel IL-17A- and IL-17F-inhibiting Nanobody designed to target difficult-to-reach sites of inflammation due to its small size and albumin-binding domain.…
Abstract Number: 0380 • ACR Convergence 2025
Multidimensional Health Assessment Questionnaire (MDHAQ)/RAPID3, is an Useful Tool to Assess Comorbid and Residual Fatigue in Rheumatoid Arthritis Patients
Rosa Maria Morlà Novell¹, Beatriz Frade Sosa², Maria López-Lasanta³, Meritxell Sallés Lizarzáburu⁴, Noemí Busquets Pérez⁵, Georgina Salvador Alarcón⁶, Marta Valls Roc⁷, Virginia Ruiz-Esquide⁸, Lola Tobalina Mastre⁹, Raimon Sanmartí⁸ and José Gomez-Puerta¹⁰, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ³Hospital Universitari Vall d´Hebron, Barcelona, Spain, ⁴Xarxa Sanitària Althaia Manresa, Manresa, Spain, ⁵Hospital de Granollers, Granollers, Spain, ⁶Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁷Hospital Universitari Dr Trueta, Girona, Sudan, ⁸Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁹IDIBAPS. Hospital Clinic de Barcelona, Barcelona, ¹⁰Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Fatigue is a highly prevalent (40%-70%)1 comorbidity in rheumatoid arthritis (RA) patients, and residual fatigue has been described in a significant proportion of patients…
Abstract Number: 0176 • ACR Convergence 2025
Development and Validation of an Accurate Patient Reported Outcome Measure-based Disease Activity Score to Enable Remote Monitoring in RA
Agnes Looijen¹, Paco Welsing², Sytske Anne Bergstra³, Annette van der Helm-van Mil³ and Pascal de Jong⁴, ¹Erasmus MC, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, ³LUMC, Leiden, Netherlands, ⁴Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands
Background/Purpose: For RA patients, regular monitoring of disease activity is essential, but in-person assessments may not always be feasible due to the increasing pressure on…
Abstract Number: 2564 • ACR Convergence 2025
An illustration-based patient-reported outcome measure reveals concealed symptoms in patients with rheumatoid arthritis and the factor contributing to the discrepancy between patient and evaluator global assessments
Mie Fusama¹, Hideko Nakahara², Megumi Okada³, Kayoko Sakagami⁴, Ikuyo Noguchi⁵, Harumi Matsumura⁶, Hiroaki Ito⁴, Kosaku Oda⁵, Yoshitaka Shinto³, Kenshi Higami⁶, Satomi Higami⁶ and Tetsuya Tomita⁷, ¹Kansai University of International Studies, Miki, Japan, ²Osaka Yukioka College of Health Science, Ibaraki, Osaka, Japan, ³Shinto Orthopaedics and Rheumatology Clinic, Osaka, Japan, ⁴Infusion Clinic, Osaka, Japan, ⁵Oda Orthopedic Surgery Rheumatology Clinic, Nishinomiya, Japan, ⁶Higami Clinic of Rheumatology and Diabetology, Kashihara, Japan, ⁷Morinomiya University of Medical Sciences, Osaka, Japan
Background/Purpose: RA patients frequently encounter challenges in effectively communicating their symptoms to medical professionals. Recently, the “Okomarigoto Sheet” (OS), an illustration-based patient-reported outcome measure for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].